Discovery calls templates and swipe files for healthcare and life sciences in the Middle East
Copy-and-paste starting points for discovery calls — plus notes on why each template works and how to adapt it. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Middle East.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install discovery calls has to be shaped to that reality from day one.
Templates are only useful if you understand why they work. Every swipe file below is paired with the underlying principle so you can adapt rather than copy blind.
Template one: the trigger-first opener. Reference an observable event in the first sentence. This works because everything after discovery is downstream of what you learned in it — the buyer sees you know something specific about their moment.
Template two: the concrete-outcome subject line. Name a number, a metric, or a decision. Vagueness is invisible in a full inbox.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Discovery calls is only useful here when it is pointed at both constraints at once.
Template three: the single-question CTA. Ask one question the recipient can answer in under thirty seconds. Multi-question emails get skipped, not answered.
Template four: the internal weekly review deck. Six slides: list health, trigger volume, discovery-to-opportunity conversion, wins, losses, next week's bets. Keep the same six every week.
Template five: the kill-criteria doc. Written before you launch, listing exactly which numbers cause you to stop. Prevents the sunk-cost debate.
Adaptation rules: change nouns and numbers, not structure. If a template stops working, revisit the principle before you swap templates.
Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing discovery calls deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Sales · healthcare · Middle East — answered
- Does discovery calls work for healthcare and life sciences in the Middle East?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing. The healthcare teams that install this get past procurement instead of dying in it.
- Can I use these templates as-is?
- Yes for structure, no for wording. Change the specifics to match your ICP.
- How often should templates be refreshed?
- Structure holds for a year; wording tends to fatigue in a quarter.
- What is the most-overlooked template?
- Kill criteria. Written before launch, it prevents most of the wasted spend later.
- Do templates apply to enterprise discovery calls?
- Yes, with heavier governance. Structure remains the same.
- What is the Middle East-specific pitfall when running discovery calls for healthcare?
- Importing a playbook that was built for another market. In the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing — the install has to reflect that.
Growth Broker editorial
Filed under sales · healthcare · middle east